白细胞介素12B rs3212227基因多态性与肝细胞癌发生相关性的Meta分析

目的系统评价白细胞介素12B（IL-12B）rs3212227基因多态性与肝细胞癌发病风险的相关性。 方法计算机检索CNKI、万方、维普、Pubmed、Medline及OVID等数据库，纳入含有IL-12B rs3212227多态性与肝细胞癌相关性信息的文献。由2位研究者按照纳入标准进行文献筛选及数据提取，使用STATA 14.0软件进行Meta分析，并采用Eggr's检验识别发表偏倚。 结果共纳入8篇研究，在共显性模型（AC vs. AA）中，IL-12B rs3212227基因多态性与肝细胞癌无明显相关性（Z= 1.84，P= 0.065），而在等位基因模型（C vs. A）、显性模型（CC+ AC vs. AA）、隐性模型（CC vs. AC+ AA）及共显性模型（CC vs. AA）中，C基因型可增加肝细胞癌的发病风险（Z= 2.90，P= 0.004；Z= 3.12，P= 0.002；Z= 2.26，P= 0.024；Z= 2.92，P= 0.003）。分层分析中，以随机人群为来源的研究，在显性模型（CC+ AC vs. AA）中，IL-12B rs3212227基因多态性与肝细胞癌存在相关性OR= 1.17，95%CI（1.01，1.35），Z= 2.04，P= 0.041]，以医院人群为来源的研究，除共显性模型（AC vs. AA）外OR= 1.12，95%CI（0.93，1.36），Z= 1.22，P= 0.222]，而等位基因模型（C vs. A）OR= 1.16，95%CI（1.03，1.30），Z= 2.54，P= 0.011]、显性模型（CC+ AC vs. AA）OR= 1.22，95%CI（1.04，1.43），Z= 2.39，P= 0.017]，隐性模型（CC vs. AC+ AA）OR= 1.25，95%CI（1.03，1.53），Z= 2.26，P= 0.024]和共显性模型（CC vs. AA）OR= 1.37，95%CI（1.09，1.73），Z= 2.69，P= 0.007]模型与肝细胞癌存在相关性。 结论IL-12B rs3212227基因多态性与肝细胞癌存在相关性，C基因型可增加肝细胞癌的发病风险。

Meta-analysis of the association between interleukin-12B rs3212227 polymorphism and hepatocellular carcinoma

ObjectiveTo systemically explore the association between interleukin 12B (IL-12B) rs3212227 polymorphism and risk of hepatocellular carcinoma. MethodSystematic searches were conducted in CNKI, Wanfang data, VIP, PubMed, Medline and OVID to collect the articles with relevant information of IL-12B rs3212227 polymorphism and hepatocellular carcinoma. Two reviewers independently screened articles and extracted data according to the inclusion criteria. The STATA 14.0 software was used to perform Meta analysis. The Eggr's test was applied to evaluate the publication bias. ResultsA total of 8 studies were included. In the co-dominant model (AC vs. AA), IL-12B rs3212227 polymorphism was not associated with hepatocellular carcinoma (Z= 1.84, P= 0.065), while in allele model (C vs. A), dominant model (CC+ AC vs. AA), implicit model (CC vs. AC+ AA) and co-dominant model (CC vs. AA), C genotype increased the risk of hepatocellular carcinoma (Z= 2.90, P= 0.004; Z= 3.12, P= 0.002; Z= 2.26, P= 0.024; Z= 2.92, P= 0.003). For the stratified analysis, in the population-based study, IL-12B rs3212227 polymorphism was associated with hepatocellular carcinoma in the dominant model (CC+ AC vs. AA)OR= 1.17, 95%CI(1.01, 1.35), Z= 2.04, P= 0.041], and in the hospital-based study, IL-12B rs3212227 polymorphism was associated with hepatocellular carcinoma in allele model (C vs. A)OR= 1.16, 95%CI(1.03, 1.30), Z= 2.54, P= 0.011], dominant model (CC+ AC vs. AA)OR= 1.22, 95%CI (1.04, 1.43), Z= 2.39, P= 0.017], implicit model (CC vs. AC+ AA)OR= 1.25, 95%CI (1.03, 1.53), Z= 2.26, P= 0.024] and co-dominant model (CC vs. AA)OR= 1.37, 95%CI (1.09, 1.73), Z= 2.69, P= 0.007], except for the co-dominant model (AC vs. AA)OR= 1.12, 95%CI (0.93, 1.36), Z= 1.22, P= 0.222]. ConclusionIL-12B rs3212227 polymorphism is associated with hepatocellular carcinoma and the C genotype can increase the hepatocellular carcinoma risk.